Institution
Trakya University
Education•Edirne, Turkey•
About: Trakya University is a education organization based out in Edirne, Turkey. It is known for research contribution in the topics: Population & Medicine. The organization has 2727 authors who have published 5490 publications receiving 76048 citations. The organization is also known as: University of Thrace & Trakya Üniversitesi.
Topics: Population, Medicine, Cancer, Lung cancer, Magnetic field
Papers published on a yearly basis
Papers
More filters
••
Yale University1, Erasmus University Rotterdam2, University of British Columbia3, University of California, Los Angeles4, University of Tsukuba5, Complutense University of Madrid6, University of Sheffield7, National and Kapodistrian University of Athens8, University of Washington9, Akdeniz University10, National Cheng Kung University11, University of Tübingen12, University of Würzburg13, University of Ulsan14, University of Turin15, Rambam Health Care Campus16, University of Verona17, University of Barcelona18, Pompeu Fabra University19, Trakya University20, İnönü University21, Cornell University22, Wayne State University23, Eli Lilly and Company24, Queen Mary University of London25, University of Nebraska Medical Center26
TL;DR: Additional follow-up supports that ramucirumab plus docetaxel significantly improves progression-free survival, without a significant improvement in overall survival, for patients with platinum-refractory advanced urothelial carcinoma.
Abstract: Summary Background Ramucirumab—an IgG1 vascular endothelial growth factor receptor 2 antagonist—plus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of overall survival results for the RANGE trial. Methods We did a randomised, double-blind, phase 3 trial in patients with advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy. Patients were enrolled from 124 investigative sites (hospitals, clinics, and academic centres) in 23 countries. Previous treatment with one immune checkpoint inhibitor was permitted. Patients were randomly assigned (1:1) using an interactive web response system to receive intravenous ramucirumab 10 mg/kg or placebo 10 mg/kg volume equivalent followed by intravenous docetaxel 75 mg/m2 (60 mg/m2 in Korea, Taiwan, and Japan) on day 1 of a 21-day cycle. Treatment continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met. Randomisation was stratified by geographical region, Eastern Cooperative Oncology Group performance status at baseline, and visceral metastasis. Progression-free survival (the primary endpoint) and overall survival (a key secondary endpoint) were assessed in the intention-to-treat population. The study is registered with ClinicalTrials.gov , NCT02426125 ; patient enrolment is complete and the last patient on treatment is being followed up for safety issues. Findings Between July 20, 2015, and April 4, 2017, 530 patients were randomly allocated to ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267) and comprised the intention-to-treat population. At database lock (March 21, 2018) for the final overall survival analysis, median follow-up was 7·4 months (IQR 3·5–13·9). In our sensitivity analysis of investigator-assessed progression-free survival at the overall survival database lock, median progression-free survival remained significantly improved with ramucirumab compared with placebo (4·1 months [95% CI 3·3–4·8] vs 2·8 months [2·6–2·9]; HR 0·696 [95% CI 0·573–0·845]; p=0·0002). Median overall survival was 9·4 months (95% CI 7·9–11·4) in the ramucirumab group versus 7·9 months (7·0–9·3) in the placebo group (stratified HR 0·887 [95% CI 0·724–1·086]; p=0·25). Grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients and with an incidence more than 2% higher with ramucirumab than with placebo were febrile neutropenia (24 [9%] of 258 patients in the ramucirumab group vs 16 [6%] of 265 patients in the placebo group) and neutropenia (17 [7%] of 258 vs six [2%] of 265). Serious adverse events were similar between groups (112 [43%] of 258 patients in the ramucirumab group vs 107 [40%] of 265 patients in the placebo group). Adverse events related to study treatment and leading to death occurred in eight (3%) patients in the ramucirumab group versus five (2%) patients in the placebo group. Interpretation Additional follow-up supports that ramucirumab plus docetaxel significantly improves progression-free survival, without a significant improvement in overall survival, for patients with platinum-refractory advanced urothelial carcinoma. Clinically meaningful benefit might be restricted in an unselected population. Funding Eli Lilly and Company.
60 citations
••
TL;DR: In this paper, the possible use of activated hazelnut shell ash and activated bentonite as the adsorbents of Cr(VI) from synthetic solutions and the effect of operating parameters were investigated.
60 citations
••
TL;DR: This study suggests that D. magna resting eggs can be exploited as an attractive alternative chitin source.
60 citations
••
TL;DR: It was found that methylene blue infusion did not change cytokine levels or outcome in severe sepsis, and the administration ofethylene blue, however, resulted in a transient increase in arterial pressure.
Abstract: The aim of our study was to assess the effect of methylene blue infusion on plasma levels of cytokines in severe sepsis. In a prospective, randomized, double-blind, placebo-controlled study, patients received either methylene blue 0.5 mg.kg-1.h-1 (MB group, n = 15) or similar volume of isotonic saline (control group, n = 15) i.v. for 6 hours. Plasma concentrations of tumour necrosis factor-alpha, interleukin-1, interleukin-2 receptor, interleukin-6, interleukin-8 were measured by sensitive immunoassays at basal (15 min before start of the study), immediately after, and at 24 and 48 hours after methylene blue infusion. We evaluated haemodynamic parameters (mean arterial pressure, heart rate), blood gases, methaemoglobin levels, and biochemical parameters at the same time. Methylene blue administration had no significant effect on plasma cytokine levels, blood gases and biochemical parameters. When compared to placebo infusion in controls, methylene blue administration resulted in significantly higher mean arterial pressure (85 +/- 14 mmHg vs 74.1 +/- 10.3 mmHg; P < 0.01), and methaemoglobin levels (1.06 +/- 0.22% vs 0.9 +/- 0.05%; P < 0.05). Furthermore, comparison with baseline levels revealed significantly increased both mean arterial pressure (85 +/- 14 mmHg and 74.1 +/- 10.2 mmHg; P < 0.05) and methaemoglobin levels (1.06 +/- 0.22% and 0.88 +/- 0.06%; P < 0.05) in MB group. There was no difference in mortality rates between the groups. We found that methylene blue infusion did not change cytokine levels or outcome in severe sepsis. The administration of methylene blue, however, resulted in a transient increase in arterial pressure. Because of the limited size of the present study, and the short period of observation, our findings need to be confirmed by larger clinical trials of methylene blue infused in a dose-titrated manner.
60 citations
••
TL;DR: Findings revealed that male students' use of the Internet was more problematic compared to female students' and social interaction anxiety was found to be among the predictors of problematic Internet use.
Abstract: The current study investigated the relationship between problematic Internet use and social interaction anxiety among pre-service teachers. Participants were 1235 students attending teacher training programs at a Turkish state university. The ''Problematic Internet Use Scale'' and ''Social Interaction Anxiety Scale'' were used to collect the data. Independent-samples t-test and one-way ANOVA were conducted to examine the differences; and correlation and regression analyses were used to examine the relationships between variables. Findings revealed that male students' use of the Internet was more problematic compared to female students'. As the time spent on the Internet increased, so did the problematic Internet use levels. In addition, the problematic Internet use levels of students varied with regard to departments. A significant relationship was found between the level of problematic Internet use and social interaction anxiety, and social interaction anxiety was found to be among the predictors of problematic Internet use. Implications and suggestions for further research are provided.
60 citations
Authors
Showing all 2798 results
Name | H-index | Papers | Citations |
---|---|---|---|
Mehmet Kaya | 95 | 751 | 35759 |
A. O. Barut | 42 | 327 | 8833 |
Levent Öztürk | 41 | 128 | 5663 |
Mehmet Kanter | 40 | 148 | 6045 |
Ronni Wolf | 40 | 248 | 5059 |
Michael P. Steinmetz | 36 | 205 | 4513 |
Yalçın Tüzün | 35 | 135 | 4724 |
Necdet Sut | 34 | 250 | 3950 |
Metin Aydogdu | 31 | 95 | 4302 |
Mustafa Yildiz | 31 | 441 | 4129 |
Alparslan Turan | 30 | 175 | 4113 |
Dilek Memiş | 30 | 113 | 3127 |
Alparslan Turan | 28 | 78 | 3702 |
Omer Coskun | 28 | 89 | 3193 |
Oguz Karabay | 27 | 232 | 2602 |